OPK
HealthcareOPKO Health, Inc. · Biotechnology · $960M
What is OPKO Health, Inc.?
OPKO Health operates across diagnostics and pharmaceuticals, serving patients and providers in the United States and multiple international markets including Ireland, Israel, Chile, and Spain.
Through its BioReference Laboratories unit, OPKO delivers a broad range of laboratory testing services — from molecular diagnostics to women's health and correctional healthcare. Its pharmaceutical arm develops and commercializes specialty drugs, including Rayaldee for chronic kidney disease patients, alongside pipeline candidates targeting diabetes, obesity, and growth hormone deficiencies.
Founded in 1995 and headquartered in Miami, Florida.
- BioReference laboratory testing services
- Rayaldee (chronic kidney disease treatment)
- 4Kscore prostate cancer testing
- Pipeline pharmaceutical candidates including OPK88003 and hGH-CTP
Is OPK a Good Stock to Buy?
UQS Score rates OPK as Poor overall.
The Risk pillar stands out as the one area of relative strength in OPK's profile, suggesting the balance sheet carries less immediate distress than the broader score might imply.
Quality, Moat, and Growth all register as Weak, while Valuation appears Elevated — a combination that raises meaningful questions for investors weighing risk against potential reward.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does OPK pay dividends?
No — OPKO Health, Inc. does not currently pay a dividend.
OPKO Health does not currently pay a dividend. Given its active pharmaceutical pipeline and ongoing clinical-stage investments, available capital is directed toward research, development, and business operations rather than shareholder distributions.
When does OPK report earnings?
OPKO Health reports earnings on a quarterly cadence, consistent with US-listed equities.
The company's results reflect the dual pressures of a diagnostics business facing competitive reimbursement dynamics and a pharmaceutical segment still advancing pipeline candidates toward commercialization. Revenue trends across both segments bear watching given the Weak Growth pillar rating.
For the most recent quarter's results, visit OPKO Health's investor relations page directly.
OPK Price History
-68.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in OPKO Health, Inc.?
Based on OPKO Health, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does OPKO Health do?
OPKO Health operates in two segments: diagnostics, through BioReference Laboratories, and pharmaceuticals. The diagnostics arm provides laboratory testing services across a wide range of disease areas, while the pharmaceutical segment develops and markets specialty drugs and pipeline therapies targeting conditions like chronic kidney disease, diabetes, and growth hormone deficiency.
Does OPK pay dividends?
No, OPKO Health does not pay a dividend. The company reinvests available resources into its pharmaceutical pipeline and diagnostics operations rather than returning cash to shareholders through distributions.
When does OPK report earnings?
OPKO Health follows a standard quarterly reporting schedule. For confirmed dates and the most recent financial results, check the investor relations section of the company's official website.
Is OPK a good stock to buy?
UQS Score rates OPK as Poor, with Weak readings across Quality, Moat, and Growth pillars and an Elevated Valuation. That combination warrants careful consideration. The full pillar analysis is available to Pro members on uqs-score.com.
Is OPK overvalued?
The UQS Valuation pillar for OPK is rated Elevated, suggesting the current market price may not be well-supported by the company's underlying fundamentals. Investors should weigh this against the Weak quality and growth profile.
What is OPK's market cap bracket?
OPKO Health is classified as a small-cap stock, placing it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers.
Is OPK a long-term quality investment?
As a long-term quality indicator, the UQS Score rates OPK as Poor. Weak moat and growth signals alongside an elevated valuation suggest limited structural advantages at this time. Pro members can access the complete analysis to inform their own assessment.
What sector does OPK belong to?
OPKO Health operates in the Healthcare sector, spanning both diagnostics services and specialty pharmaceuticals — two sub-industries with distinct competitive dynamics, reimbursement pressures, and regulatory considerations.
Unlock Full OPK Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Moat, Growth, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare OPK against diagnostics and pharma peers side by side
- ✓Track score changes over time as new data is published
Pro Analysis
OPK — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 17, 2026 | 18.1 | 2.9 | 16.0 | 5.4 | 81.9 | 0.0 | 0.0 |
| May 1, 2026 | 18.1 | 2.9 | 16.0 | 5.4 | 81.8 | 0.0 | 0.0 |
| Apr 2, 2026 | 18.1 | 2.9 | 16.0 | 5.7 | 81.8 | 0.0 | — |
OPK — Pillar Breakdown
Quality
— 2.9/100 (25%)OPKO Health, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 5.4/100 (20%)OPKO Health, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 81.9/100 (15%)OPKO Health, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)OPKO Health, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 16/100 (25%)OPKO Health, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for OPK.
Score Composition
Financial Data
More Stock Analysis
How is the OPK UQS Score Calculated?
The UQS (Unified Quality Score) for OPKO Health, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses OPKO Health, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether OPKO Health, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.